viral vector

Chemogenetic therapies for epilepsy: promises and challenges

Expression of Gi-coupled designer receptors exclusively activated by designer drugs (DREADDs) on excitatory hippocampal neurons in the hippocampus represents a potential new therapeutic strategy for drug-resistant epilepsy. During my talk I will demonstrate that we obtained potent suppression of spontaneous epileptic seizures in mouse and a rat models for temporal lobe epilepsy using different DREADD ligands, up to one year after viral vector expression. The chemogenetic approach clearly outperforms the seizure-suppressing efficacy of currently existing anti-epileptic drugs. Besides the promises, I will also present some of the challenges associated with a potential chemogenetic therapy, including constitutive DREADD activity, tolerance effects, risk for toxicity, paradoxical excitatory effects in non-epileptic hippocampal tissue.

Time-course of motor behavioural, neurodegenerative and neuroinflammatory changes after viral vector-mediated overexpression of alpha-synuclein in the mouse substantia nigra

An updated suite of viral vectors for in-vivo calcium imaging using local and retro-orbital injections

Using viral vectors to study the synergistic developmental effects of tau, alpha-synuclein and amyloid-beta

Achieving cell-type specific transduction with adeno-associated viral vectors in pigeons (Columba livia)

FENS Forum 2024

Chronic visualization of microcirculation in mice using viral vectors expressing fluorescent protein-fused albumin

FENS Forum 2024

Development of a novel viral vector-based model of dementia with Lewy bodies in mice

FENS Forum 2024

Novel viral vectors for cell-type specific overexpression of alpha-synuclein

FENS Forum 2024

Therapeutic administration of the Borna virus X protein by a viral vector AAV10 in a mouse model of ALS

FENS Forum 2024

Viral vector manipulation of neurons activated by fear learning in the centromedial amygdala

FENS Forum 2024